From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
 | Gene Ontology term | %1 | Univariate P -value2 | FDR-adjusted P -value3 |
---|---|---|---|---|
B/P Cluster | Immunoglobulin | 34.5 | 4.6E-25 | 1.8E-23 |
 | Immunoglobulin V-set | 37.9 | 2.6E-18 | 2.5E-17 |
 | Antigen binding | 27.6 | 8.7E-16 | 1.2E-14 |
 | Immunoglobulin-like fold | 44.8 | 9.7E-16 | 4.8E-15 |
 | Immune response | 41.4 | 2.0E-13 | 2.6E-11 |
T/NK Cluster | Positive regulation of immune system process | 24.4 | 1.7E-08 | 2.5E-05 |
 | Natural killer cell mediated cytotoxicity | 19.5 | 9.7E-07 | 5.9E-05 |
 | Positive regulation of lymphocyte activation | 17.1 | 3.3E-07 | 6.9E-05 |
 | T cell | 12.2 | 1.3E-06 | 7.2E-05 |
 | Positive regulation of lymphocyte differentiation | 12.2 | 3.7E-06 | 3.3E-04 |
M/D Cluster | MHC class II, alpha/beta chain, N-terminal | 39.1 | 7.0E-22 | 3.4E-20 |
 | Class II histocompatibility antigen | 39.1 | 1.3E-19 | 1.9E-18 |
 | MHC class II protein complex | 39.1 | 4.6E-20 | 3.3E-18 |
 | Immunoglobulin C1-set | 43.5 | 7.0E-18 | 1.7E-16 |
 | Antigen processing and presentation | 47.8 | 1.3E-18 | 3.0E-16 |